European Healthtech startup funding raised during H1 2021.
In H1 2021, 231 European Healthtech companies raised a combined €3.9B across 233 funding rounds, up 56.9% versus H1 2020. UK led by capital raised, and Accel was the most active investor. Data as of 9 Jul 2026.
| Company | Stage | Date | Amount |
|---|---|---|---|
| Kry | Series D+ | Apr 2021 | €262M |
| Oxford Nanopore Technologies | Other | May 2021 | €225M |
| Quanta | Series D+ | Jun 2021 | €205M |
| Immunocore | Debt | Feb 2021 |
17 exits · €1.4B disclosed.
| Arvelle Therapeutics | Acquisition | Jan 2021 | €784M |
| Babylon | IPO | Jun 2021 | €470M |
| Ginolis | Acquisition | Feb 2021 | €70M |
| MatTek | Acquisition | Mar 2021 | €57M |
| €190M |
| Atai Life Sciences | Series D+ | Mar 2021 | €131M |
| IO Biotech | Series B | Jan 2021 | €127M |
| Huma | Series C | May 2021 | €107M |
| CeQur | Series C | Apr 2021 | €97M |
| Melio | Series C | Jan 2021 | €90M |
| Evox Therapeutics | Series C | Feb 2021 | €80M |
| Monte Rosa | Series C | Mar 2021 | €80M |
| Lumicks | Other | Apr 2021 | €77M |
| Ada health | Series B | May 2021 | €74M |
| Alchemab Therapeutics | Series A | Apr 2021 | €69M |
| Kaia Health | Series D+ | Apr 2021 | €62M |
